Navigation Links
Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
Date:4/21/2008

BATON ROUGE, La., April 21 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline. The report found America's pharmaceutical research companies are testing a record 750 new medicines to help treat cancer.

"We released this report in Baton Rouge because of its particular relevance to the health of the population in Louisiana," says PhRMA Senior Vice President Ken Johnson. The report was unveiled at the State Capitol Building. "According to the Centers for Disease Control and Prevention, Louisiana has the highest death rate from cancer in the United States. In fact, recent data from the American Cancer Society tells us that African American men in Louisiana have the highest death rate and shortest survival rate in the country for all cancers combined, which is why we are releasing this report here to coincide with National Cancer Minority Awareness Week."

The medicines in the report are being tested in human clinical trials or are awaiting approval by the U.S. Food and Drug Administration.

"The medicines now in the research pipeline will add to the substantial progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments," notes PhRMA President and CEO Billy Tauzin. "This strong commitment to research is a product of the determination of the men and women working for America's pharmaceutical research companies to develop new medicines that will enable patients to live longer, healthier, and more productive lives. I am one of those patients who was diagnosed with cancer and was given a new treatment that brought me from the brink of death back to life."

Cancer medicines being developed include 113 for lung cancer, the leading cause of cancer death in the United States; 90 for breast cancer, which is expected to strike more than 180,000 American women this year; 65 for colorectal cancer, which is the third most common cancer in both men and women; and 88 for prostate cancer, which this year is expected to kill 28,000 American men. Additional medicines target brain cancer, kidney cancer, ovarian cancer, pancreatic cancer, skin cancer and others.

The medicines represent many cutting-edge approaches, including one medicine that targets and kills specific cancer cells, and then activates the patient's general immune system to destroy any remaining cancer.

"Researchers are making exciting progress in the search for new cures and treatments for cancer. But these efforts are wasted if the medicines we develop aren't accessible to patients who need them," says Johnson.

Help is available to patients in need through the Partnership for Prescription Assistance, a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped nearly 5 million patients nationwide, including more than 112,000 people in Louisiana. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,000 cities to educate people about patient assistance programs. The PPA bus has been to Louisiana seven times since the program was launched. Just last month, the bus, along with Montel Williams, was in Baton Rouge for a special event at the Louisiana State Capitol.

The "Help is Here Express" is staffed by trained specialists able to quickly help uninsured patients in need access information on more than 475 patient assistance programs, including nearly 200 programs offered by pharmaceutical companies. When the "Help is Here Express" moves on, patients can visit PPA's easy-to-use Web site (http://www.pparx.org) or call the toll-free phone number (1-888-4PPA-NOW).

To read the Medicines in Development for Cancer 2008 on the PhRMA web site, click on the following link: http://www.phrma.org

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org/

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org/

For information on the dangers of imported drugs, visit: http://www.buysafedrugs.info/

CONTACT: Pamela Squires of the Pharmaceutical Research and Manufacturers of America, +1-202-835-3460


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
2. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
5. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
6. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
7. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
8. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
9. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
10. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic Tests ... Medical Devices sector report , "Alzheimer ... provides an overview of Alzheimer Diagnostic Tests currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Ross A. Clevens, MD, FACS , ... a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, a ... performing cosmetic procedures including injectables, fillers and laser treatments. A master ...
(Date:2/10/2016)... TN (PRWEB) , ... February 09, 2016 , ... ... to sports concussion, yet the cause of injury may be one of many ... two-day advanced PT Continuing Education Course , Mastering Rehab Solutions for ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... Worth, Texas (PRWEB) , ... February 09, 2016 ... ... and reconstruction firm helping businesses recover after a disaster, announced today the acquisition ... service companies in Hawaii. , “Investing in like-minded companies who excel ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products ... newest mobility device, the StandUp Walker. Made entirely in the USA, the StandUp ... 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of ...
Breaking Medicine News(10 mins):